HYTERA
21.4.2022 14:20:12 CEST | Business Wire | Press release
Hytera (SZSE: 002583), the leading global provider of professional communications technologies and solutions, has released its annual Corporate Responsibility Report recently, summarizing the company’s environmental, social and governance (ESG) performance in 2021.
As a leading player in the Professional Mobile Radio (PMR) industry, Hytera has a long history of providing stakeholders with transparent information on its annual sales and ESG performance. The report features successes achieved last year, including its performance on business development as well as environmental sustainability, as well as technical support for public events and disaster relief around the world.
Continuous Innovation to Lead the Industry Transformation
Hytera is focused on technological innovation to drive business development. By the end of 2021, Hytera's total R&D investment had increased to USD 162 million, accounting for 18.05% of the sales revenue, and R&D personnel accounted for over 40% of the staff. Hytera has filed for 2,892 patents in total, including 507 PCT patents, 291 overseas patents, and 79 5G and LEO satellites patents; the overall patent licensing rate has reached 93.32%.
Hytera’s PMR-LTE convergent solutions have been recognized by the market in the past few years and so far, Hytera has deployed more than 200 converged multi-media PTT platforms globally and has been cooperating with over 20 local operators to better serve more vertical industry uses. In 2021, the International Critical Communications Awards (ICAA) awarded Hytera the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC customer case using PMR-LTE convergent solutions.
Better Operation for Environmental Sustainability
Hytera is dedicated to operating with sustainable business practices, including energy saving, emission reduction, and green and recyclable product manufacturing management. In 2021, Hytera’s electricity consumption decreased by 25% YOY, and general industrial waste dropped by 22% YOY.
In 2021, Hytera's subsidiaries HMF and Teltronic have organized multiple Green Travel campaigns, which reduced 809 kg of carbon dioxide emissions, exhaust gas and noise pollution by bike cycling instead of car driving in commutes to work.
Participation in Social Activities and Community Service to Repay the Society
Hytera has actively contributed its capabilities to improve disease prevention, for example, donating two-way radios to staff in hospitals, medical teams and security departments around the world in order to combat COVID-19.
Hytera also actively participated in various social welfare activities. In late 2021, Hytera supported Tinzert Elementary School of Morocco with a donation of warm coats and medical masks, and renovated the school to withstand the coldness of the mountainous area. Besides, Hytera was recognized as the science and technology education center and set up technology tutorials for both students and adults utilizing the PMR technologies and devices.
In terms of disaster relief, Hytera provided professional communication supports to the local rescue teams for flood relief in Henan China, and western Germany. Hytera also provided support to Blue Sky Rescue (BSR) volunteers in Europe to empower their post-disaster rescue work.
This year, the world faced greater global challenges than ever before, necessitating the use of professional technologies and products. Hytera’s innovations in communications technologies are revolutionizing industries and addressing some of the society's serious challenges.
Hytera is proud of its efforts to protect the environment and keep the community safe, and everything it does is guided by the code of ethics and business conduct.
Hytera will continue to make contributions to the people, communities, and the environment in order to make the world more intelligently connected and to help shape a better future for everybody.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005570/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom